Diabetes and obesity drug; GLP-1 receptor agonist with tissue-wide impact
This week has seen several medical research and regulatory developments. A mid‑stage trial has reported that Insilico Medicine’s experimental drug rentosertib altered blood‑protein patterns that aging clocks read as three to four years younger; Stanford teams have published studies transplanting human cortical organoids into mice and identifying separate developmental origins for hindbrain neurons; and US health officials have named permanent directors for three FDA centers, stabilising leadership after months of upheaval.
New lawsuits claim GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition. Regulators are reviewing evidence, while manufacturers dispute the claims. Reports cite studies showing mixed results on risk, with the absolute risk remaining very low.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
[Synopsis here]
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
The wedding dress market is shifting as GLP-1 weight loss drugs become common among engaged couples. Designers report earlier fittings, changed guarantees, and rising alterations costs. Brides worry about weight loss before weddings, while sales staff push early purchases and flexible guarantees.
Vivani Medical is developing a long-acting semaglutide implant to deliver GLP-1 therapy over months, potentially replacing injections. Novo Nordisk is evaluating the device to improve adherence and reduce weight regain, but regulatory and cost questions remain as trials proceed.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Lilly has filed six lawsuits targeting online sellers and clinics marketing retatrutide, a GLP-1 drug still in Phase 3 trials for obesity and diabetes, while US authorities report a surge in illicit shipments. The company says products sold online are unverified and unapproved, and warns of substantial health risks.
PMOS, previously grouped with PCOS, affects about 1 in 8 women and involves insulin resistance and testosterone imbalance. Case studies show GLP-1 medications may improve symptoms and menstrual regularity, with trials underway. Diagnosis remains challenging and access to new treatments will depend on healthcare systems.
A BBC Business report notes rising use of weight-loss drugs in 2024-25, with a focus on male users and safety concerns, while other outlets explore personal journeys with GLP-1 medications and gut health trends.